These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

515 related articles for article (PubMed ID: 25140014)

  • 41. Vasopeptidase inhibition: a new concept in blood pressure management.
    Burnett JC
    J Hypertens Suppl; 1999 Feb; 17(1):S37-43. PubMed ID: 10340842
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi).
    Gu J; Noe A; Chandra P; Al-Fayoumi S; Ligueros-Saylan M; Sarangapani R; Maahs S; Ksander G; Rigel DF; Jeng AY; Lin TH; Zheng W; Dole WP
    J Clin Pharmacol; 2010 Apr; 50(4):401-14. PubMed ID: 19934029
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Combined Inhibition of the Renin-Angiotensin System and Neprilysin Positively Influences Complex Mitochondrial Adaptations in Progressive Experimental Heart Failure.
    Grois L; Hupf J; Reinders J; Schröder J; Dietl A; Schmid PM; Jungbauer C; Resch M; Maier LS; Luchner A; Birner C
    PLoS One; 2017; 12(1):e0169743. PubMed ID: 28076404
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Combination angiotensin receptor blocker-neutral endopeptidase inhibitor provides additive blood pressure reduction over angiotensin receptor blocker alone.
    Bloch MJ; Basile JN
    J Clin Hypertens (Greenwich); 2010 Oct; 12(10):809-12. PubMed ID: 21029344
    [No Abstract]   [Full Text] [Related]  

  • 45. Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy.
    von Lueder TG; Wang BH; Kompa AR; Huang L; Webb R; Jordaan P; Atar D; Krum H
    Circ Heart Fail; 2015 Jan; 8(1):71-8. PubMed ID: 25362207
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Angiotensin receptor/neprilysin inhibitor-a breakthrough in chronic heart failure therapy: summary of subanalysis on PARADIGM-HF trial findings.
    Książczyk M; Lelonek M
    Heart Fail Rev; 2020 May; 25(3):393-402. PubMed ID: 31713710
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Angiotensin receptor-neprilysin inhibitor in patients with heart failure and chronic kidney disease.
    Cho IJ; Kang SM
    Kidney Res Clin Pract; 2021 Dec; 40(4):555-565. PubMed ID: 34922429
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Focus on the Novel Cardiovascular Drug LZC696: from Evidence to Clinical Consideration.
    Lin LM; Wu Y; Wu MF; Lin JX
    Cardiovasc Drugs Ther; 2016 Dec; 30(6):623-633. PubMed ID: 27858191
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-term neprilysin inhibition - implications for ARNIs.
    Campbell DJ
    Nat Rev Cardiol; 2017 Mar; 14(3):171-186. PubMed ID: 27974807
    [TBL] [Abstract][Full Text] [Related]  

  • 50. LCZ696, an angiotensin receptor-neprilysin inhibitor, improves cardiac function with the attenuation of fibrosis in heart failure with reduced ejection fraction in streptozotocin-induced diabetic mice.
    Suematsu Y; Miura S; Goto M; Matsuo Y; Arimura T; Kuwano T; Imaizumi S; Iwata A; Yahiro E; Saku K
    Eur J Heart Fail; 2016 Apr; 18(4):386-93. PubMed ID: 26749570
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Angiotensin-Neprilysin Inhibition as a Paradigm for All?
    Vaduganathan M; Desai AS
    Curr Cardiol Rep; 2016 Nov; 18(11):115. PubMed ID: 27747488
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan: Insights From a Combined PARAGON-HF and PARADIGM-HF Analysis.
    Rohde LE; Claggett BL; Wolsk E; Packer M; Zile M; Swedberg K; Rouleau J; Pfeffer MA; Desai AS; Lund LH; Kober L; Anand I; Merkely B; Senni M; Shi V; Rizkala A; Lefkowitz M; McMurray JJV; Solomon SD
    Circ Heart Fail; 2021 Mar; 14(3):e008052. PubMed ID: 33706551
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacogenomics of angiotensin receptor/neprilysin inhibitor and its long-term side effects.
    Krittanawong C; Kitai T
    Cardiovasc Ther; 2017 Aug; 35(4):. PubMed ID: 28489317
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The path to an angiotensin receptor antagonist-neprilysin inhibitor in the treatment of heart failure.
    Braunwald E
    J Am Coll Cardiol; 2015 Mar; 65(10):1029-41. PubMed ID: 25766951
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Selective Inhibition of the C-Domain of ACE (Angiotensin-Converting Enzyme) Combined With Inhibition of NEP (Neprilysin): A Potential New Therapy for Hypertension.
    Alves-Lopes R; Montezano AC; Neves KB; Harvey A; Rios FJ; Skiba DS; Arendse LB; Guzik TJ; Graham D; Poglitsch M; Sturrock E; Touyz RM
    Hypertension; 2021 Sep; 78(3):604-616. PubMed ID: 34304582
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
    Anand IS; Bishu K; Rector TS; Ishani A; Kuskowski MA; Cohn JN
    Circulation; 2009 Oct; 120(16):1577-84. PubMed ID: 19805651
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Current evidence of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction.
    Abumayyaleh M; El-Battrawy I; Behnes M; Borggrefe M; Akin I
    Future Cardiol; 2020 Jul; 16(4):227-236. PubMed ID: 32186406
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Role of Angiotensin Receptor-Neprilysin Inhibition in Heart Failure.
    Prenner SB; Shah SJ; Yancy CW
    Curr Atheroscler Rep; 2016 Aug; 18(8):48. PubMed ID: 27324636
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial.
    Jhund PS; Claggett B; Packer M; Zile MR; Voors AA; Pieske B; Lefkowitz M; Shi V; Bransford T; McMurray JJ; Solomon SD
    Eur J Heart Fail; 2014 Jun; 16(6):671-7. PubMed ID: 24692284
    [TBL] [Abstract][Full Text] [Related]  

  • 60. LCZ696, Angiotensin II Receptor-Neprilysin Inhibitor, Ameliorates High-Salt-Induced Hypertension and Cardiovascular Injury More Than Valsartan Alone.
    Kusaka H; Sueta D; Koibuchi N; Hasegawa Y; Nakagawa T; Lin B; Ogawa H; Kim-Mitsuyama S
    Am J Hypertens; 2015 Dec; 28(12):1409-17. PubMed ID: 25762811
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.